FY2024 EPS Estimates for Gilead Sciences, Inc. Reduced by Cantor Fitzgerald (NASDAQ:GILD)

Gilead Sciences, Inc. (NASDAQ:GILD) – Research analysts at Cantor Fitzgerald decreased their FY2024 EPS estimates for Gilead Sciences in a research note issued on Monday, April 22nd. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will post earnings per share of $4.10 for the year, down from their previous estimate of $7.19. Cantor Fitzgerald currently has a “Neutral” rating and a $78.00 price objective on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $6.28 per share.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The business had revenue of $7.12 billion for the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the business posted $1.67 earnings per share.

A number of other research firms have also commented on GILD. Mizuho lowered their price objective on shares of Gilead Sciences from $101.00 to $90.00 and set a “buy” rating on the stock in a research note on Thursday, February 22nd. Truist Financial downgraded Gilead Sciences from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $91.00 to $82.00 in a research note on Thursday, February 22nd. Barclays lowered their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating on the stock in a report on Monday, February 12th. Wells Fargo & Company cut their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an “equal weight” rating for the company in a report on Monday, March 4th. Finally, StockNews.com downgraded shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, April 19th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has an average rating of “Hold” and an average price target of $84.71.

Gilead Sciences Stock Up 0.1 %

GILD stock opened at $67.03 on Wednesday. The firm’s 50-day moving average is $71.68 and its two-hundred day moving average is $76.46. The company has a market capitalization of $83.46 billion, a price-to-earnings ratio of 14.90, a price-to-earnings-growth ratio of 0.96 and a beta of 0.19. Gilead Sciences has a 52 week low of $65.90 and a 52 week high of $87.86. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08.

Institutional Trading of Gilead Sciences

Several large investors have recently added to or reduced their stakes in GILD. Nilsine Partners LLC boosted its holdings in Gilead Sciences by 1.1% in the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock worth $891,000 after purchasing an additional 127 shares in the last quarter. Etesian Wealth Advisors Inc. increased its holdings in shares of Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares during the last quarter. Financial Counselors Inc. raised its stake in shares of Gilead Sciences by 1.5% in the 4th quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after acquiring an additional 128 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in Gilead Sciences by 3.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 130 shares during the last quarter. Finally, Institutional & Family Asset Management LLC boosted its position in Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 140 shares during the period. 83.67% of the stock is owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.29% of the company’s stock.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a dividend of $0.77 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a dividend yield of 4.59%. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is currently 68.44%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.